Visceral Leishmaniasis after Anti-Interleukin 17A (IL-17A) Therapy in a Patient Affected by Psoriatic Arthritis
- PMID: 36288060
- PMCID: PMC9609957
- DOI: 10.3390/tropicalmed7100319
Visceral Leishmaniasis after Anti-Interleukin 17A (IL-17A) Therapy in a Patient Affected by Psoriatic Arthritis
Abstract
The reactivation of latent Leishmania infection in chronic diseases and immunocompromised hosts is a broad and heterogeneous field in medicine and infectious diseases. We reported one of the first cases of Visceral Leishmaniasis occurring in a Caucasian middle-aged man living in an endemic country (Italy) for Leishmania infantum infection following secukinumab treatment for psoriatic arthritis. The patient was cured with a Liposomal Amphotericin B (L-AmB, 3 mg/Kg on days 1-5, followed by a dose on days 10, 17, 24, 31 and 38) regimen, after which his anti-interleukin 17 treatment was restarted-without recurrence in the follow-up.
Keywords: Leishmania; arthritis; interleukin-17; psoriasis; secukinumab.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
References
-
- Pitta M.G., Romano A., Cabantous S., Henri S., Hammad A., Kouriba B., Argiro L., El Kheir M., Bucheton B., Mary C., et al. IL-17 and IL-22 are associated with protection against human kala azar caused by Leishmania donovani. J. Clin. Investig. 2009;119:2379–2387. doi: 10.1172/JCI38813. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
